Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients

W. A. Pettinger, K. Keeton, K. Tanaka

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


A radioimmunoassay for the new angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II), was developed and applied to pharmacologic studies in rats and hypertensive man. Specificity of the assay was established using naturally occurring angiotensins, potential saralasin metabolites, and other synthetic angiotensin analogues. Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min. The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min. These observations suggest that metabolites of saralasin do not accumulate in sufficient quantity in man or rat to interfere with the assay. The biochemical half-life of 3.2 min is consistent with infusion time of less than 20 min required to achieve a stable plasma concentration and pharmacologic activity of saralasin during constant saralasin infusion into hypertensive man. These studies provide a rational basis of future experimental design for saralasin and possibly other peptide analogues.

Original languageEnglish (US)
Pages (from-to)146-158
Number of pages13
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Feb 1975
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients'. Together they form a unique fingerprint.

Cite this